CareersInvestor RelationsCOVID-19
  1. Home
  2. Medical Imaging
  3. Molecular Imaging
  4. PET/CT Scanners
  5. Biograph Vision
Biograph Vision

Biograph VisionSee a whole new world of precision.

Biograph Vision™1 is the next-generation of PET/CT scanners that empowers you to see a whole new world of precision. It goes beyond digital to reveal the bigger picture, maximize efficiency and help you to better understand disease progression.

AIDAN

AIDAN Platform

The intelligent scanner platform for PET/CT.

  • Become more efficient
  • Personalize your scans
  • Standardize your exams 

Особливості

Siemens Healthineers Biograph Vision

  1. Exclusive bed design and wide bore

    Zero differential deflection for accurate attenuation correction and TG-66 compliant along with a 78-cm bore to support bariatric imaging and easier positioning of radiation oncology devices

  2. 3.2 mm LSO crystals

    For improved, more precise imaging

  3. Optiso UDR detector

    100% SiPM coverage of the LSO array

  4. CT capability

    Definition class CT offers 64- or 128-Edge-slice CT configurations

  5. iMAR (Optional)

    Iterative algorithm for metal artifact reduction

  6. SAFIRE (Optional)

    CT iterative reconstruction to reduce dose and maintain image quality

  7. Whole-body dynamic imaging (Optional)

    Routine whole-body dynamic imaging enable by FlowMotion™ continuous bed motion

  8. QualityGuard (Optional)

    Uses intrinsic radioactive properties of Lutetium present on LSO detectors to automatically calibrate itself

  9. FlowMotion AI (Optional)

    Personalize scans based on anatomy and standardize imaging protocols based on indication

  10. FAST PET Workflow AI (Optional)

    Creation of Auto Ranges and Auto Data Export

  11. Multiparametric PET Suite AI (Optional)

    Adds the metabolic rate and distribution volume to the standard SUV image without the need for an invasive measurement

  12. OncoFreeze™ / OncoFreeze AI (Optional)

    Motion management without extending scan time and, if preferred, without the need for a gating device

Accuracy to reveal the bigger picture

Accuracy to reveal the bigger picture

Biograph Vision is specifically designed to break through the limits of spatial and temporal resolution. With 3.2-mm crystals, Biograph Vision delivers high spatial resolution to reduce the impact of partial volume effect (PVE). Along with higher spatial resolution, a faster time of-flight also makes it easier to see small lesions2. This helps you quantify more accurately and more confidently understand disease progression.

Professor Ronald Boellard, PhD University Medical Center Groningen, Groningen, The Netherlands
“…by improving the spatial resolution…you have less partial volume effect, so you get sharper images and more accurate quantification.”
Professor Ronald Boellard, PhD University Medical Center Groningen, Groningen, The Netherlands
Professor Ronald Boellard, PhD University Medical Center Groningen, Groningen, The Netherlands
Performance to maximize efficiency

Performance to maximize efficiency

Biograph Vision can help you optimize your clinical operations with quality images and efficient workflow. With the market’s highest effective sensitivity at 100 cps/kBq3 and the fastest time-of flight in the industry4 Biograph Vision can not only reduce scan time and injected dose to boost productivity, it can also improve image quality. Combined with FlowMotion, it is designed to reduce unnecessary exposure to CT radiation, provide greater patient comfort, and decrease examination times.2

Professor John Prior, PhD, MD, FEBNM Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
“We have now already, as compared to the older system, reduced the activity we inject… Now it's probably 30% faster with about 30% less dose which is something very acceptable.” 2
Professor John Prior, PhD, MD, FEBNM Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Professor John Prior, PhD, MD, FEBNM Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Reproducibility to understand disease progression

Reproducibility to understand disease progression

Biograph Vision can help reduce unwarranted variations to maximize patient care. Its zero-differential-deflection patient bed provides perfect registration between the CT and PET fields of view, ensuring accurate attenuation correction for more precise quantification. QualityGuard5 automates daily and weekly quality control without a radioactive source to help produce consistent and accurate results. FlowMotion Multiparametric PET Suite makes it easier and faster to perform parametric imaging in daily clinical routine. It is completely automated and integrated into the PET/CT workflow for more reproducible images.

Richard E. Carson, PhD Yale PET Center Yale School of Medicine, New Haven, CT, USA
“Being more quantitative, our reproducibility can be that much better, and it may matter when we’re trying to do a repeat scan early on in a therapy and decide what to do.”
Richard E. Carson, PhD Yale PET Center Yale School of Medicine, New Haven, CT, USA
Richard E. Carson, PhD Yale PET Center Yale School of Medicine, New Haven, CT, USA

Making vision a reality

Watch the full-length documentary video on how Biograph Vision became a reality.

Клінічне використання

  1. Normal brain metabolism in a subject with suspected multi-system atrophy
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 1. Normal brain metabolism in a subject with suspected multi-system atrophy

    Normal brain study with sharp delineation of functioning cortex and increased contrast between cortex and white matter.

    Clinical detail
    A 67-year-old male with progressive muscular stiffness, difficulty in swallowing, and autonomic dysfunctions with no response to levodopa therapy; undergoing evaluation for striatal multi-system atrophy. A Fludeoxyglucose F 18 Injection.* (18F FDG) PET/CT scan of the brain was performed on Biograph Vision™. The study shows normal uptake in brain with excellent delineation of functioning cortex and sharp contrast between cortex and white matter. Additionally there is sharp basal ganglial edge definition, especially the sharp margins and distinct separation of the head of caudate nucleus and putamen.
    Biography Vision clinical image brain
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 1. Normal brain metabolism in a subject with suspected multi-system atrophy

    Normal brain study with sharp delineation of functioning cortex and increased contrast between cortex and white matter.

    Examination protocol
    Biograph Vision , 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay.CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.

    * Indications and Important Safety Information.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
  2. Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
    Data courtesy of UMCG, Groningen, The Netherlands.

    Case 2. Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition

    Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18 FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.

    Clinical detail
    A 73-year-old male with prostate cancer treated with brachytherapy presented with biochemical relapse. The patient underwent PET/CT study following injection of androgen receptor imaging agent 18F –dihydrotestosterone (18F-FDHT) in order to assess presence of androgen receptor positive recurrence. PET/CT was performed on Biograph Vision™. Images showed tracer within cardiac and vascular blood pool as well as in the liver. Significant clearance of tracer through the biliary tract and gall bladder, kidneys, and intestines is visualized. No well defined focal uptake suggestive of androgen receptor-avid metastatic lesions is visualized, although primary prostate bed showed significant uptake on higher intensity images. Sharp delineation of vascular structures, especially cavernous and sigmoid sinuses as well as carotid and subclavian vessels reflect the high overall image quality and low noise level in the Biograph Vision images.
    Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 2. Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition

    Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18 FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.

    Examination protocol
    Biograph Vision , 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay.CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.

    [a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be gauranteed. Please contact your local Siemens organization for further details.
    Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 2. Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition

    Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18 FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.

    Examination protocol
    Biograph Vision , 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay.CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.

    [a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
    Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 2. Visualization of vascular blood pool during whole-body dynamic PET/CT acquisition

    Fluoro-dihydrotestosterone (18F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after[a] 18F FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.

    Examination protocol
    Biograph Vision , 5.4 mCi (200 MBq)18F FDG, 51 minutes post-injection delay.CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.

    [a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
  3. Visualization of 7 mm lymph node metastases
    Data courtesy of UMCG, Groningen, The Netherlands.

    Case 3

    Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer

    68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.

    Clinical detail
    A 78-year-old male with primary prostate cancer underwent 68Ga-PSMA PET/CT initial staging. PET/CT was performed on Biograph Vision™. The images showed high tracer uptake in kidneys, salivary glands, and bladder, which are at physiologically normal levels. The liver, spleen, and intestines also show lower but normal levels of uptake as well. There is also focal hypermetabolism in the prostate reflecting primary tumor and the small hypermetabolic right external iliac lymph node is suggestive of solitary nodal metastases. No other PSMA-avid metastatic lesions are visualized. Sharply delineated renal, salivary gland, bladder, and intestinal margins reflect the high overall image quality and low background noise level in the Biograph Vision images.
    Visualization of 7 mm lymph node metastases
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 3

    Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer

    68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.


    Examination protocol
    Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay.CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.

    [a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be gauranteed. Please contact your local Siemens organization for further details.
    Visualization of 7 mm lymph node metastases
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 3

    Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer

    68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.


    Examination protocol
    Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay.CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.

    [a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be gauranteed. Please contact your local Siemens organization for further details.
    Visualization of 7 mm lymph node metastases
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 3

    Visualization of 7 mm lymph node metastases on 68Ga-PSMA[a] evaluation of primary prostate cancer

    68Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.


    Examination protocol
    Biograph Vision, 2.7 mCi (100 MBq) 68Ga-PSMA, 1 hour 45 minutes post-injection delay.CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.

    [a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be gauranteed. Please contact your local Siemens organization for further details.
  4. High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen
    Data courtesy of UMCG, Groningen, The Netherlands.

    Case 4

    High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT

    Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.

    Clinical detail
    A 49-year-old woman with a history of operated ovarian carcinoma with suspected recurrence underwent 18F FDG PET/CT for restaging. A PET/CT was performed on Biograph Vision™. The images showed hypermetabolic metastases in the right obturator node, anterior pelvic wall above, and adjacent to the bladder as well as multiple small liver metastases in the posterior aspect of the right lobe (Segment VII) and in the caudate lobe. Sharp delineation of small liver lesions with high contrast compared to normal liver without respiratory gating reflect the overall high image quality and high lesion contrast to background in the Biograph Vision images.
    High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 4

    High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT

    Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.


    Examination protocol
    Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay.CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.

    * Indications and Important Safety Information.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be gauranteed. Please contact your local Siemens organization for further details.
    High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 4

    High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT

    Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.


    Examination protocol
    Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay.CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.

    * Indications and Important Safety Information.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be gauranteed. Please contact your local Siemens organization for further details.
    High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 4

    High contrast in pelvic nodal and hepatic metastases in a patient with operated ovarian carcinoma seen by 18F FDG* PET/CT

    Hypermetabolic right obturator and liver metastases visualized with high contrast on 18F FDG PET/CT in a patient with operated ovarian carcinoma.


    Examination protocol
    Biograph Vision, 7.5 mCi (280 MBq) 18 FDG, 1 hour 49 minutes post-injection delay.CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.

    * Indications and Important Safety Information.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be gauranteed. Please contact your local Siemens organization for further details.
  5. Small liver metastases in a patient with operated colorectal carcinoma detected
    Data courtesy of UMCG, Groningen, The Netherlands.

    Case 5

    Small liver metastases in a patient with operated colorectal carcinoma detected with 18F FDG* PET/CT

    Small hypermetabolic foci in the right lobe of liver close to the diaphragm visualized with high contrast and minimal motion related blurring with 18F FDG PET/CT.

    Clinical detail
    A 69-year-old male with a history of operated colorectal carcinoma with suspected recurrence underwent 18F FDG PET/CT for restaging. A PET/CT was performed on Biograph Vision™. The images showed sharp delineation of small hypermetabolic metastasis in the right lobe of liver near the dome of diaphragm (Segment VII). Intense uptake in the abdominal wall is suggestive of metastatic deposit. Mildly increased uptake in mediastinal lymph nodes are possibly secondary to inflammation. High contrast of small liver metastases without significant motion related blurring even without respiratory gating reflects high overall image quality and increased lesion contrast to background in the Biograph Vision images.
    Small liver metastases in a patient with operated colorectal carcinoma detected
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 5

    Small liver metastases in a patient with operated colorectal carcinoma detected with 18F FDG* PET/CT

    Small hypermetabolic foci in the right lobe of liver close to the diaphragm visualized with high contrast and minimal motion related blurring with 18F FDG PET/CT.


    Examination protocol
    Biograph Vision, 7.3 mCi (270 MBq) 18F FDG, 1 hour 50 minutes post-injection delay.CT: 100 kV, 10 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

    * Indications and Important Safety Information.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be gauranteed. Please contact your local Siemens organization for further details.
  6. 18F-Fluroestradiol PET/CT in a patient with breast carcinoma
    Data courtesy of UMCG, Groningen, The Netherlands.

    Case 6

    18F-Fluroestradiol [a] PET/CT in a patient with breast carcinoma

    Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with 18F-Fluoroestradiol (FES).

    Clinical detail
    A 77-year-old female with a history of breast carcinoma treated with left mastectomy and chemo-radiotherapy presented with pain in the thoracic wall along with pleural effusion. The patient underwent 18F Fluoroestradiol (FES) PET/CT to assess presence of estrogen receptor (ER) positive metastases. A PET/CT was performed on Biograph Vision™. High resolution PET images show faint uptake in the left pleura suggestive of ER positive pleural thickening. The PET/CT images also sharply delineates physiological uptake in the gall bladder and biliary tract and intestine reflecting hepatobiliary clearance of tracer. Sharp definition of biliary tree with high contrast compared to background even at 440 x 440 matrix reconstructed resolution reflect the high overall image quality of the Biograph Vision images.
    18F-Fluroestradiol PET/CT in a patient with breast carcinoma
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 6

    18F-Fluroestradiol [a] PET/CT in a patient with breast carcinoma

    Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with 18F-Fluoroestradiol (FES).


    Examination protocol
    Biograph Vision, 5.2 mCi (195 MBq) 18 F FES, 1 hour 29 minutes post-injection delay.CT: 100 kV, 13 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

    [a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be gauranteed. Please contact your local Siemens organization for further details.
    18F-Fluroestradiol PET/CT in a patient with breast carcinoma
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 6

    18F-Fluroestradiol [a] PET/CT in a patient with breast carcinoma

    Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with 18F-Fluoroestradiol (FES).


    Examination protocol
    Biograph Vision, 5.2 mCi (195 MBq) 18 F FES, 1 hour 29 minutes post-injection delay.CT: 100 kV, 13 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

    [a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be gauranteed. Please contact your local Siemens organization for further details.
  7. Sharp delineation of physiological uptake in vascular walls, marrow, and intestine
    Data courtesy of UMCG, Groningen, The Netherlands.

    Case 7

    Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG * PET/CT

    Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in 18F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.

    Clinical detail
    A 79-year-old male with unknown clinical history. A PET/CT was performed on Biograph Vision™. High resolution PET images show sharp delineation of physiological uptake in the aortic walls, atrial walls, carotid, and subclavian vessels. Normal marrow uptake within vertebrae, ribs, and pelvis are well visualized. Physiological uptake in the gastric mucosa and intestines, with note made of sharply delineated descending colon. Sharp delineation of normal structures like rib and vessels with low background uptake reflect high overall image quality even at 440x440 matrix reconstructed resolution of the Biograph Vision images.
    Sharp delineation of physiological uptake in vascular walls, marrow, and intestine
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 7

    Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with 18F FDG * PET/CT

    Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in 18F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.


    Examination protocol
    Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay.CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

    * Indications and Important Safety Information.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
    Sharp delineation of physiological uptake in vascular walls, marrow, and intestine
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 7

    FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.


    Examination protocol
    Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay.CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

    * Indications and Important Safety Information.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
  8. Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases
    Data courtesy of UMCG, Groningen, The Netherlands.

    Case 8

    Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG* PET/CT

    Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in 18F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.

    Clinical detail
    70-year-old male. Though clinical history unknown, there are obviously multiple metastases as shown on PET/CT performed on the Biograph Vision™ . High resolution PET images show multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae and soft tissue. Sharp delineation with high lesion contrast of small metastases in the vertebrae, pelvis, mediastinal nodes and soft tissue especially in the left thigh reflect the high image quality even at 440x440 matrix reconstructed resolution of the Biograph Vision images.
    Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 8

    Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG * PET/CT

    Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in 18F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.


    Examination protocol
    Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay.CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

    * Indications and Important Safety Information.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
    Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases
    Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.

    Case 8

    Delineation of multiple skeletal, lymph node, liver, and soft tissue metastases with 18F FDG * PET/CT

    Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in 18F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.


    Examination protocol
    Biograph Vision, 8.2 mCi (305 MBq) 18F FDG, 1 hour 41 minutes post-injection delay.CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

    * Indications and Important Safety Information.
    Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

Технічні особливості

Transcend digital with the Optiso UDR detector

Transcend digital with the Optiso UDR detector

Optiso UDR’s proprietary 3.2 mm LSO crystals move silicon photomultiplier (SiPM) technology beyond digital to a new level of precision to help you detect small lesions, devise accurate treatment strategies and achieve optimal performance in a wide range of count rates.

See a whole new world of precision

LSO scintillator
3.2mm crystals
SiPm Technology
Optiso UDR detector

For faster time-of-flight and better image quality

Siemens is the only PET manufacturer that owns the entire manufacturing process of the detector. It allows us to closely control the process quality and gives the flexibility to explore different detector designs.
  • Grown, cut, and individually selected in-house
  • Self-manufactured to enable precise specifications and complete detector redesign
  • Higher light output and faster scintillation1, enabling faster time-of-flight and better image quality

Disclaimer
Biograph Vision and its features and applications are not commercially available in all countries. Their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
1 Compared to BGO crystals.
2 Compared to competitive literature available at time of publication. Data on file.
3 Data courtesy of Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
4 Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
5 Based on internal typical measurements at time of publication. Data on file.
6 Compared to current Siemens state-of-the-art technologies. Data on file.
7 Images for illustration purposes only. Data acquired on Biograph mCT system.
68Ga: Data courtesy of University of Erlangen, Erlangen, Germany
18F: Data courtesy of Kantonsspital Baselland, Liestal, Switzerland
11C: Data courtesy of West Virginia University, Morgantown, West Virginia, USA
82Rb: Data courtesy of Central Manchester University Hospitals, Manchester, UK

 

Технічні характеристики

Gantry

Bore diameter

78 cm

Tunnel length

136 cm

Table capacity

227 kg (500 lb)

CT

Generator power

80 kW (100 kW optional)

Rotation times

0.33, 0.305, 0.285 s

Tube voltages

70, 80, 100, 120, 140 kV

Iterative reconstruction

SAFIRE5

Metal artifact reduction

iMAR5

Slices

64, 128

PET

Axial field of view

26.3 cm

Crystal size

3.2 x 3.2 x 20 mm

SiPM coverage of crystal array

100%

Effective sensitivity

100 cps/kBq

Effective NEC

1870 kcps

Time of flight performance

214 ps

1Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

2Compared to current state-of-the-art technologies. Data on file.

3Based on internal measurements available at time of publication. Data on file.

4Based on competitive literature available at time of publication. Data on file.

5Optional.

The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.